it is meant to cover the collection of information on adverse drug reactions (ADRs), at pre- and post-marketing stage, the scientific evaluation of these ADR reports and the regulatory decisions which may have to taken following their analysis. These regulatory decisions may include in extreme cases withdrawal or suspension of the marketing authorization, but more often, a modification of th elegal status of the drug and amendments or warnings in the summary of products characteristics, labelling and package leaflet